David Parrot, Chief Financial Officer at Scribe Therapeutics, Inc. (SCTX), bought 1,333 shares at $15.00 ($20K) on 2026-07-23, disclosed to the SEC on 2026-07-27.
Scribe Therapeutics CFO David Parrot purchased 1,333 shares for $20,000, marking the largest insider purchase in the company's history. This significant buy by C-suite leadership suggests confidence in the company's genetic editing technology and its recent market performance.
The stock is currently trading at $18.86, representing a 25.47% discount from its 52-week high of $25.31, following a 67% surge after its upsized IPO on July 24.
Insider purchase is a rare reversal as the stock is currently trading 25.47% below its 52-week high, indicating the stock may be overbought following the recent IPO pop.
Something here stands out, but not much.